Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New hope for AML patients: study tests better drug to keep leukemia away after transplant

NCT ID NCT07463651

First seen Mar 17, 2026 · Last updated May 23, 2026 · Updated 11 times

Summary

This study tests whether a newer drug, gilteritinib, works better than the current standard, sorafenib, to prevent leukemia from coming back after a stem cell transplant. About 594 adults and teens with a specific genetic mutation (FLT3-ITD) will be randomly assigned to take one of the two drugs for up to two years. The goal is to see which drug keeps patients free of detectable cancer cells longer and improves survival.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA (AML) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Ruijin Hospital, Shanghai Jiaotong University School of Medicine

    RECRUITING

    Shanghai, Shanghai Municipality, 200025, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • the First Affiliated Hosptital of Soochow University

    RECRUITING

    Suzhou, Jiangsu, 215006, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.